CD19 and acute lymphoblastic leukemia: Successful molecular remission was demonstrated in two infants with relapsed refractory CD19+ B cell ALL with a single dose of UCART19 cells infused after administering lymphodepleting chemotherapy and anti-CD52 serotherapy.